FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 359:85-87 July 3, 2008 Number 1 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

Infections caused by Staphylococcus aureus, particularly those that are resistant to methicillin and all available β-lactam antibiotics — the so-called methicillin-resistant S. aureus (MRSA) infections — have been declared a public health imperative. A recent report from the Centers for Disease Control and Prevention¹ estimated that 18,650 persons in the United States died from invasive MRSA infections in 2005. A new therapeutic approach to the management of these infections would therefore be welcome.

The development of new antibiotics to treat MRSA infections has slowed for complex reasons.² Some researchers have pointed to a lack of "new" microbial targets. Indeed, most . . . [Full Text of this Article]

Source Information

From the Department of Pediatrics, Section of Infectious Diseases, University of Chicago, Chicago.

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.